# US 2013/0158051 A1 · Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158051 A1
- Document ID: US20130158051A1
- Status: Published application
- Kind: A1
- Application number: 13/521,829
- Filed: 2011-01-12
- Published: 2013-06-20
- Earliest claimed: 2010-01-13
- Assignees: Sanofi
- Inventors: Dieter Kadereit; Matthias Schaefer; Stephanie Hachtel; Axel Dietrich; Thomas Huebschle; Andreas Gille; Katrin Hiss
- Web page: https://patentgrep.com/patent/US20130158051A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2, R3, R4, X and Y are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

## Claims

### Claim 1

A compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of such a compound or such a salt,
wherein
A is selected from the group consisting of NH, O and S;
X is selected from the group consisting of (C1-C6)-alkanediyl, (C2-C6)-alkenediyl, (C2-C6)-alkynediyl, (C3-C7)-cycloalkanediyl and (C1-C6)-alkanediyloxy, all of which are optionally substituted by one or more identical or different substituents selected from the group consisting of fluorine and hydroxyl, where the oxygen atom of the (C1-C6)-alkanediyloxy group is attached to the group R2;
Y is a 4-membered to 7-membered saturated or partially unsaturated monocyclic or bicyclic heterocycle which, in addition to the ring nitrogen atom shown in formula I, contains 0, 1, 2 or 3 identical or different ring heteroatoms selected from the group consisting of N, O and S, where one or two, of the additional ring nitrogen atoms may carry a hydrogen atom or a (C1-C4)-alkyl substituent and one of the ring sulfur atoms may carry one or two oxo groups and where the heterocycle is optionally substituted at one or more ring carbon atoms by identical or different (C1-C4)-alkyl substituents;
R1 is selected from the group consisting of (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C3-C7)-cycloalkyl-CtH2t— and Het-CtH2t—, in which t is selected from the group consisting of 0, 1, 2 and 3;
R2 is selected from the group consisting of phenylene and a bivalent radical of an aromatic 5-membered or 6-membered monocyclic heterocycle which contains 1, 2 or 3 identical or different ring heteroatoms selected from the group consisting of N, O and S, where one of the ring nitrogen atoms may carry a hydrogen atom or a substituent R21 and where the phenylene and the bivalent radical of an aromatic heterocycle are optionally substituted at one or more ring carbon atoms by identical or different substituents R22;
R3 is selected from the group consisting of (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C3-C7)-cycloalkyl-CuH2u— and Het-CvH2v—, in which u and v are selected from the group consisting of 1 and 2, or R3 is a radical of a saturated or unsaturated 3-membered to 10-membered monocyclic or bicyclic ring which contains 0, 1, 2, 3 or 4 identical or different ring heteroatoms selected from the group consisting of N, O and S, where one or two of the ring nitrogen atoms may carry a hydrogen atom or a (C1-C4)-alkyl substituent and one or two of the ring sulfur atoms may carry one or two oxo groups and where the radical of a ring is optionally substituted at one or more ring carbon atoms by identical or different substituents R31, with the proviso that R3 may not represent (C1-C6)-alkyl if A represents S;
R4 is selected from the group consisting of hydrogen, (C1-C4)-alkyl and (C3-C7)-cycloalkyl-CzH2z—, where z is selected from the group consisting of 0, 1 and 2;
R21 is selected from the group consisting of (C1-C4)-alkyl and (C3-C7)-cycloalkyl-CwH2w— and oxy, where w is selected from the group consisting of 0, 1 and 2;
R22 is selected from the group consisting of halogen, hydroxyl, (C1-C4)-alkyl-, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m—, amino, nitro, cyano, hydroxycarbonyl, (C1-C4)-alkyloxycarbonyl, aminocarbonyl and aminosulfonyl;
R31 is selected from the group consisting of halogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl, hydroxyl, (C1-C4)-alkyloxy, oxo, (C1-C4)-alkyl-S(O)m—, amino, (C1-C4)-alkylamino, di((C1-C4)-alkyl)amino, (C1-C4)-alkylcarbonylamino, (C1-C4)-alkylsulfonylamino, nitro, cyano, (C1-C4)-alkylcarbonyl, aminosulfonyl, (C1-C4)-alkylaminosulfonyl and di((C1-C4)-alkyl)aminosulfonyl;
Het is a radical of a saturated 4-membered to 7-membered monocyclic heterocycle which contains 1 or 2 identical or different ring heteroatoms selected from the group consisting of N, O and S and which is attached via a ring carbon atom, where the radical of a heterocycle is optionally substituted by one or more identical or different substituents selected from the group consisting of fluorine and (C1-C4)-alkyl;
m is selected from the group consisting of 0, 1 and 2, where all numbers m are independent of one another;
where all cycloalkyl and cycloalkanediyl groups independently of one another and independently of other substituents are optionally substituted by one or more identical or different substituents which are selected from the group consisting of fluorine and (C1-C4)-alkyl;
where all alkyl, alkanediyl, CtH2t, CuH2u, CwH2w, CvH2v, alkenyl, alkenediyl, alkynyl and alkynediyl groups independently of one another and independently of other substituents are optionally substituted by one or more fluorine substituents.

### Claim 2 (depends on 1)

The compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of such a compound or such a salt as claimed in claim 1, wherein A is selected from the group consisting of O and S.

### Claim 3 (depends on 1)

The compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of such a compound or such a salt as claimed in claim 1, wherein X is selected from the group consisting of (C1-C6)-alkanediyl, (C2-C6)-alkenediyl and (C1-C6)-alkanediyloxy.

### Claim 4 (depends on 1)

The compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of such a compound or such a salt as claimed in claim 1, wherein
Y is a 4-membered to 7-membered saturated monocyclic or bicyclic heterocycle which, in addition to the ring nitrogen atom shown in formula I, contains 0 or 1 ring heteroatom selected from the group consisting of N, O and S, where the additional ring nitrogen atom may carry a hydrogen atom or a (C1-C4)-alkyl substituent and the ring sulfur atom may carry one or two oxo groups and where the heterocycle is optionally substituted at one or more ring carbon atoms by identical or different (C1-C4)-alkyl substituents.

### Claim 5 (depends on 1)

The compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of such a compound or such a salt as claimed in claim 1 wherein
R1 is selected from the group consisting of (C1-C6)-alkyl and (C3-C7)-cycloalkyl-CtH2t—, where t is selected from the group consisting of 0, 1 and 2.

### Claim 6 (depends on 1)

The compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of such a compound or such a salt as claimed in claim 1 wherein R2 is selected from the group consisting of phenylene and pyridindiyl, where the phenylene and the pyridinediyl are optionally substituted at one or more ring carbon atoms by identical or different substituents R22.

### Claim 7 (depends on 1)

The compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of such a compound or such a salt as claimed in claim 1 wherein
R3 is selected from the group consisting of (C1-C6)-alkyl, (C3-C7)-cycloalkyl-CuH2u— and Het-CvH2v—, in which u and v are selected from the group consisting of 1 and 2, or R3 is the radical of a saturated or unsaturated 3-membered to 10-membered monocyclic or bicyclic ring which contains 0, 1 or 2 identical or different ring heteroatoms selected from the group consisting of N, O and S, where one or two of the ring nitrogen atoms may carry a hydrogen atom or a (C1-C4)-alkyl substituent and one of the ring sulfur atoms may carry one or two oxo groups and where the radical of a ring is optionally substituted at one or more ring carbon atoms by identical or different substituents R31, with the proviso that R3 may not represent (C1-C6)-alkyl if A represents S;
Het is a radical of a saturated 4-membered to 6-membered monocyclic heterocycle which contains 1 ring heteroatom selected from the group consisting of N, O and S and which is attached via a ring carbon atom, where the radical of a heterocycle is optionally substituted by one or more identical or different substituents selected from the group consisting of fluorine and (C1-C4)-alkyl.

### Claim 8 (depends on 1)

The compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of such a compound or such a salt as claimed in claim 1 wherein A is selected from the group consisting of O and S;
X is selected from the group consisting of (C1-C6)-alkanediyl, (C2-C6)-alkenediyl and (C1-C6)-alkanediyloxy;
Y is a 4-membered to 7-membered saturated monocyclic or bicyclic heterocycle which, in addition to the ring nitrogen atom shown in formula I, contains 0 or 1 ring heteroatom selected from the group consisting of N, O and S, where the additional ring nitrogen atom may carry a hydrogen atom or a (C1-C4)-alkyl substituent and the ring sulfur atom may carry one or two oxo groups and where the heterocycle is optionally substituted at one or more ring carbon atoms by identical or different (C1-C4)-alkyl substituents;
R1 is selected from the group consisting of (C1-C6)-alkyl, (C3-C7)-cycloalkyl-CtH2t— and Het-CtH2t—, where t is selected from the group consisting of 0, 1 and 2;
R2 is selected from the group consisting of phenylene and pyridinediyl, where the phenylene and the pyridinediyl are optionally substituted at one or more ring carbon atoms by identical or different substituents R22;
R3 is selected from the group consisting of (C1-C6)-alkyl, (C3-C7)-cycloalkyl-CuH2u— and Het-CvH2v—, in which u and v are selected from the group consisting of 1 and 2, or R3 is a radical of a saturated or unsaturated 3-membered to 10-membered monocyclic or bicyclic ring which contains 0, 1 or 2 identical or different ring heteroatoms selected from the group consisting of N, O and S, where one or two of the ring nitrogen atoms may carry a hydrogen atom or a (C1-C4)-alkyl substituent and one of the ring sulfur atoms may carry one or two oxo groups and where the radical of a ring is optionally substituted at one or more ring carbon atoms by identical or different substituents R31, with the proviso that R3 may not represent (C1-C6)-alkyl if A represents S;
Het is a radical of a saturated 4-membered to 6-membered monocyclic heterocycle which contains 1 ring heteroatom selected from the group consisting of N, O and S and which is attached via a ring carbon atom, where the radical of a heterocycle is optionally substituted by one or more identical or different substituents selected from the group consisting of fluorine and (C1-C4)-alkyl.

### Claim 9 (depends on 1)

The compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of such a compound or such a salt as claimed in claim 1 wherein
A is O;
X is selected from the group consisting of (C1-C6)-alkanediyl and (C1-C6)-alkanediyloxy;
Y is a 4-membered to 6-membered saturated monocyclic heterocycle which, in addition to the ring nitrogen atom shown in formula I, contains no further ring heteroatoms, where the ring is optionally substituted at one or more ring carbon atoms by identical or different (C1-C4)-alkyl substituents;
R1 is selected from the group consisting of (C1-C6)-alkyl and (C3-C7)-cycloalkyl-CtH2t—, where t is selected from the group consisting of 0 and 1;
R2 is phenylene which is optionally substituted at one or more ring carbon atoms by identical or different substituents R22;
R3 is selected from the group consisting of (C3-C7)-cycloalkyl-CuH2u— and Het-CvH2v—, in which u and v are selected from the group consisting of 1 and 2, or R3 is a radical of a saturated or unsaturated 3-membered to 7-membered monocyclic or bicyclic ring which contains 0, 1 or 2 identical or different ring heteroatoms selected from the group consisting of N, O and S, where one or two of the ring nitrogen atoms may carry a hydrogen atom or a (C1-C4)-alkyl substituent and one of the ring sulfur atoms may carry one or two oxo groups and where the radical of a ring is optionally substituted at one or more ring carbon atoms by identical or different substituents R31, with the proviso that R3 may not represent (C1-C6)-alkyl if A represents S;
R4 is selected from the group consisting of hydrogen and (C1-C4)-alkyl;
R22 is selected from the group consisting of halogen, hydroxyl, (C1-C4)-alkyl and (C1-C4)-alkyloxy;
R31 is selected from the group consisting of halogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl, hydroxyl and (C1-C4)-alkyloxy;
Het is a radical of a saturated 4-membered to 6-membered monocyclic heterocycle which contains 1 ring heteroatom selected from the group consisting of O and S and which is attached via a ring carbon atom, where the radical of a heterocycle is optionally substituted by one or more identical or different substituents selected from the group consisting of fluorine and (C1-C4)-alkyl;
where all cycloalkyl groups independently of one another and independently of other substituents are optionally substituted by one or more identical or different substituents which are selected from the group consisting of fluorine and (C1-C4)-alkyl;
where all alkyl, alkanediyl, CtH2t, CuH2u and CvH2v groups independently of one another and independently of other substituents are optionally substituted by one or more fluorine substituents.

### Claim 10 (depends on 1)

The compound of the formula I or a physiologically acceptable salt thereof or a physiologically acceptable salvate of such a compound or such a salt as claimed in claim 1, selected from the group consisting of
(S)-1-(2-{4-[5-(2,5-difluorophenoxy)-7-propoxyoxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethylphenoxy}acetyl)pyrrolidine-2-carboxylic acid
(S)-1-(2-{-4-[5-(trans-2-fluorocyclohexyloxy)-7-propoxyoxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethylphenoxy}acetyl)pyrrolidine-2-carboxylic acid
(S)-1-(2-{4-[5-(2-fluorophenoxy)-7-propoxyoxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethylphenoxy}acetyl)pyrrolidine-2-carboxylic acid
(S)-1-(2-{4-[5-(5-fluoro-2-methylphenoxy)-7-propoxyoxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethylphenoxy}acetyl)pyrrolidine-2-carboxylic acid
(S)-1-(2-{4-[5-(3-fluoro-4-methylphenoxy)-7-propoxyoxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethylphenoxy}acetyl)pyrrolidine-2-carboxylic acid
(S)-1-(2-{2,6-dimethyl-4-[7-propoxy-5-(pyridin-3-yloxy)oxazolo[5,4-d]pyrimidin-2-yl]phenoxy}acetyl)pyrrolidine-2-carboxylic acid
(S)-1-(2-{4-[5-(2,4-difluorophenoxy)-7-propoxyoxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethylphenoxy}acetyl)pyrrolidine-2-carboxylic acid
(S)-1-{2-[2,6-dimethyl-4-(5-phenoxy-7-propoxyoxazolo[5,4-d]pyrimidin-2-yl)-phenoxy]acetyl}pyrrolidine-2-carboxylic acid and
(S)-1-(2-{4-[5-(3-chlorophenoxy)-7-propoxyoxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethylphenoxy}acetyl)pyrrolidine-2-carboxylic acid

### Claim 11 (depends on 1)

A process for preparing a compound of the formula I as claimed in claim 1, wherein a compound of the formula II is reacted with a compound of the formula III,
where the groups A, X, Y, R1, R2, R3 and R4 in the compounds of the formulae II and III are defined as in the compounds of the formula I and moreover functional groups may be present in protected form or in the form of a precursor group and the group L1 is a halogen atom or a group of the formula —S(O)-Alk or —S(O)2-Alk in which Alk is (C1-C4)-alkyl.

### Claim 12 (depends on 1)

A pharmaceutical composition, comprising at least one compound of the formula I as claimed in claim 1 or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of such a compound or such a salt, and a pharmaceutically acceptable carrier.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

A method of treating wound healing disorders in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 12.

### Claim 15 (depends on 12)

A method of wound healing in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 12.

### Claim 16 (depends on 12)

A method of wound healing in diabetics in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 12.

### Claim 17 (depends on 12)

A method of treating diabetic foot syndrome in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 12.
